We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

16 hedge funds and large institutions have $891K invested in Scinai Immunotherapeutics in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

0% more ownership

Funds ownership: 0% → 0% (+0%)

11% less funds holding

Funds holding: 18 → 16 (-2)

17% less capital invested

Capital invested by funds: $1.08M → $891K (-$186K)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Holders
16
Holders Change
-2
Holders Change %
-11.11%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
1
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$280K
2
Millennium Management
Millennium Management
New York
+$36.1K
3
Morgan Stanley
Morgan Stanley
New York
+$31.4K
4
ASN
Advisory Services Network
Georgia
+$15.9K
5
TPWA
TRUE Private Wealth Advisors
Oregon
+$9.34K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$111K
2
Goldman Sachs
Goldman Sachs
New York
-$103K
3
VF
Virtu Financial
New York
-$70K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$42K
5
AIM
ARK Investment Management
Florida
-$37K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$259K +$280K +901 New
State Street
2
State Street
Massachusetts
$230K +$6.85K +22 +3%
Morgan Stanley
3
Morgan Stanley
New York
$148K +$31.4K +101 +24%
HF
4
HRT Financial
New York
$92K +$934 +3 +0.9%
TPWA
5
TRUE Private Wealth Advisors
Oregon
$43K +$9.34K +30 +25%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$39K – – –
Millennium Management
7
Millennium Management
New York
$33K +$36.1K +116 New
ASN
8
Advisory Services Network
Georgia
$14K +$15.9K +51 New
Credit Agricole
9
Credit Agricole
France
$12K – – –
Royal Bank of Canada
10
Royal Bank of Canada
Ontario, Canada
$7K – – –
UBS Group
11
UBS Group
Switzerland
$5K +$4.98K +16 New
NFG
12
Next Financial Group
Texas
$4K – – –
CAPTRUST Financial Advisors
13
CAPTRUST Financial Advisors
North Carolina
$3K – – –
Wells Fargo
14
Wells Fargo
California
$1K -$1.87K -6 -67%
GRP
15
Global Retirement Partners
California
$1K – – –
Citadel Advisors
16
Citadel Advisors
Florida
– -$111K -293 Closed
Goldman Sachs
17
Goldman Sachs
New York
– -$103K -270 Closed
VF
18
Virtu Financial
New York
– -$70K -183 Closed
Two Sigma Advisers
19
Two Sigma Advisers
New York
– -$42K -111 Closed
AIM
20
ARK Investment Management
Florida
– -$37K -98 Closed
RWB
21
RMR Wealth Builders
New Jersey
– -$1K -2 Closed

SCNI Hedge Fund Activity: Q2 2021 in Review

16 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2021, worth a combined $891K — down 17% from $1.08M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of SCNI and 4 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 4 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $280K. The largest seller was Citadel Advisors, exiting entirely with an estimated $111K sold.

  • 16 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2021, down from 18 in Q1 2021.
  • Funds reported $891K of Scinai Immunotherapeutics stock for Q2 2021, down 17% quarter-over-quarter.
  • 4 funds opened new Scinai Immunotherapeutics positions in Q2 2021 and 6 closed out, a net change of -2 holders.
  • The largest Scinai Immunotherapeutics buyer in Q2 2021 was Renaissance Technologies, an estimated $280K added.
  • The largest Scinai Immunotherapeutics seller in Q2 2021 was Citadel Advisors, an estimated $111K sold.

Based on aggregated 13F filings for Q2 2021.